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C1q is the first subcomponent of the classical pathway of the complement system and
belongs to the C1q/Tumor Necrosis Factor superfamily. C1q can perform a diverse
range of immune and non-immune functions in a complement-dependent as well as
-independent manner. Being a pattern recognition molecule of the innate immunity, C1q
can recognize a number of self, non-self and altered-self ligands and bring about effector
mechanisms designed to clear pathogens via opsonisation and inflammatory response.
C1q is locally synthesized by macrophages and dendritic cells, and thus, can get
involved in a range of biological processes, such as angiogenesis and tissue remodeling,
immune modulation, and immunologic tolerance. The notion of C1q involvement in the
pathogenesis of cancer is still evolving. C1q appears to have a dual role in cancer: tumor
promoting as well as tumor-protective, depending on the context of the disease. In the
current study, we performed a bioinformatics analysis to investigate whether C1q can
serve as a potential prognostic marker for human carcinoma. We used the Oncomine
database and the survival analysis platforms Kaplan-Meier plotter. Our results showed
that high levels of C1q have a favorable prognostic index in basal-like breast cancer
for disease-free survival, and in HER2-positive breast cancer for overall survival, while it
showed a pro-tumorigenic role of C1q in lung adenocarcinoma, and in clear cell renal cell
carcinoma. This in silico study, if validated via a retrospective study, can be a step forward
in establishing C1q as a new tool as a prognostic biomarker for various carcinoma.
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GRAPHICAL ABSTRACT | Summary of the conclusions of the study.
INTRODUCTION
C1q is the first recognition subcomponent of the complement
classical pathway, which when associated with C1r and C1s,
forms a C1 complex, allowing the activation of the complement
cascade (1). By virtue of its ability to bind to IgG and
IgM containing immune complexes and activating the classical
pathway, C1q acts as prototypical link between innate and
adaptive immune wings of the immune system (2). C1q can
bind to a range of non-self-target ligands (pathogens), altered
self (β-amyloid peptide, prion protein, apoptotic and necrotic
cells via phosphatidylserine and DNA, respectively), and cell
surface receptors (such as calreticulin and gC1qR) (3). Several
features of the C1q render it a versatile molecular sensor of
damage-modified self or non-self antigens (4). C1q, unlike most
of the complement proteins which are exclusively produced by
hepatocytes, can also be synthesized in a local environment by
a wide range of cell types including macrophages and dendritic
cells (5). Local synthesis, therefore, offers an additional avenue
to C1q in order to exert specific functions in situ that are
strictly connected to its site of production without involving
complement activation (6).
C1q is an hexametric glycoprotein of about 460 kDa,
resembling a “bouquet of tulips” being composed by three
polypeptide chains: A (28 kDa), B (25 kDa), C (24 kDa), which
are the product of three distinct genes clustered in the same
orientation, and in the order A–C–B, on a 24 kb stretch of DNA
on chromosome 1p (7). Each chain consists of a C-terminal
globular head (gC1q) domain and an N-terminal triple-helical
collagen-like (cC1q) domain (8). C1q associates with the Ca2+-
dependent C1r2-C1s2 tetramer, of about 360 kDa, to form the
soluble pentameric C1 complex (9). The C-terminal ends of A,
B and C chains assemble together to form a heterotrimeric gC1q
Abbreviations: TME, Tumor microenvironment; ECM, extracellular matrix;
BLBC, basal-like breast cancer; CCRCC, clear cell renal cell carcinoma; PRCC,
papillary renal cell carcinoma; OS, overall survival; DFS, disease-free survival;
WOX1, WW-domain containing oxidoreductase.
domain, which by virtue of its modular organization, can work
independently and engage with a diverse range of target ligands
(3). While the gC1q domain latches on to the charge patterns
on the ligands, the cC1q domain can interact with effector
mechanism inducers, such as C1r, C1s, cell surface receptors,
etc. Thus, a combination of a highly versatile and modular gC1q
domain and a cell surface interacting cC1q domain, together with
its local synthesis, makes C1q a potent orchestrator of molecular
pathways. C1q is involved not only in innate and adaptive
immune mechanisms, but also in a wide range of physiological
and pathological processes, such as placental development
(10, 11), pre-eclampsia (12, 13), wound healing (14) and
cancer (15–18).
Markiewski et al. provided evidence that C1q is present
in syngeneic mouse tumors. Indeed, they found that the
activation of the classical pathway is the major contributor to
complement-mediated tumor progression (19). Subsequently,
we showed that locally expressed C1q had important effects
in the tumor microenvironment (TME) (17). C1q expressed
in the stroma and vascular endothelium of several human
malignant tumors acted as a tumor-promoting factor by favoring
adhesion, migration and proliferation of cancer cells as well
as angiogenesis and metastasis. C1q-deficient (C1qa−/−) mice,
bearing a syngeneic B16 melanoma, exhibited slower tumor
growth and prolonged survival, compared to C3 or C5 deficient
mice although it has been shown that C3/C5 deficiency may also
create microenvironment suboptimal for tumor growth (20, 21).
Recently, we demonstrated that C1q is abundantly present in
malignant pleural mesothelioma (MPM), where it can combine
with hyaluronic acid (HA), which is a principal component of
the TME, and enhance the tumor growth by promoting cell
adhesion and proliferation (18). However, other have shown a
pro-apoptotic effect of C1q on prostate (15) and ovarian cancer
cells in vitro (16). These rather two set of contradicting studies
warranted a systematic analysis of the context of the disease and
TME that can render C1q protective or pathogenic in cancer.
In the current study, we performed a bioinformatics analysis,
using Oncomine database and the survival analysis platforms
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Kaplan-Meier plotter, in order to investigate whether C1q can
serve as a potential prognostic marker for human carcinoma, i.e.,
tumors of epithelial origin. Our results showed that high levels
of C1q have a favorable prognostic index in basal-like breast
cancer (BLBC) and in HER-2 positive breast cancer. However,
we found a pro-tumorigenic role of C1q in lung adenocarcinoma,
and in clear cell renal cell carcinoma (CCRCC). This study is an
important step forward in highlighting C1q as a new prognostic
candidate biomarker for a range of carcinomas.
METHODS
Oncomine Database Analysis
The expression levels ofC1QA,C1QB, andC1QC genes in various
carcinomas were analyzed using Oncomine (www.oncomine.
org), a cancer microarray database and web-based data mining
platform from genome-wide expression analyses (22, 23). We
compared the differences in mRNA level between normal tissue
and carcinoma. The mRNA expression levels in neoplastic tissues
compared to the healthy tissues were obtained as the parameters
of p-value < 0.05, fold change >2, and gene ranking in the
top 10%. Information about the dataset used in this study is
summarized in Supplementary Table 1.
Kaplan-Meier Plotter Database Analysis
AKaplan-Meier plotter database can be used to assess the effect of
54,675 genes on survival using 10,461 carcinoma samples (5,143
breast, 1,816 ovarian, 2,437 lung, and 1,065 gastric cancer patients
with a mean follow-up of 69/40/49/33 months) using probe sets
on the HGU133 Plus 2.0 array from Gene Expression Omnibus
(GEO). For other human carcinoma, a total of 3,439 patients with
RNAHiSeq data from The Cancer Genome Atlas (TCGA) cohort
were collected. The prognostic significance of C1QA, C1QB,
and C1QC expression and survival in several carcinomas was
analyzed by Kaplan-Meier plotter (www.kmplot.com/analysis/)
(24). The hazard ratio with 95% confidence intervals and logrank
p-value was also computed.
Immunohistochemical Analysis
Normal and neoplastic human tissues, including breast, kidney
and lung, were selected from the archives of the Department
of Pathology, University of Trieste. Immunohistochemistry
(IHC) was performed using a polymer detection method.
Briefly, tissue samples were fixed in 10% v/v buffered formalin
and then paraffin embedded. Four µm-thick tissue sections
were deparaffinized and rehydrated. The antigen unmasking
technique was carried out using Novocastra Epitope Retrieval
Solutions, pH 9 (Leica Biosystems) in a PT Link pre-treatment
module (Dako) at 98◦C for 30min. Sections were then
brought to RT and washed in PBS. After neutralization of the
endogenous peroxidase with 3% v/v H2O2 and Fc blocking
by a specific protein block (Novocastra, Leica Biosystems),
samples were incubated overnight at 4◦C with rabbit polyclonal
anti-human C1q (dilution 1:200) antibodies (Dako). Staining
was carried out via polymer detection kit (Novocastra, Leica
Biosystems) and DAB (3,3′-Diaminobenzidine; Dako, Denmark)
substrate-chromogen. Slides were counterstained with Harris
Haematoxylin (Novocastra, Leica Biosystems). Sections were
analyzed under the Axio Scope A1 optical microscope (Zeiss) and
microphotographs were collected through the Axiocam 503 color
digital camera (Zeiss) using the Zen2 software.
Statistical Analysis
Survival curves were generated by the Kaplan-Meier plotter. All
results are displayed with p-values from a log-rank test. P-values
< 0.05 were considered significant. Similarly, with Oncomine,
the statistical significance of data (p-values) was provided by
the program.
RESULTS
Bioinformatic Analysis of the Three Genes
Encoding Human C1q A, B, and C Chains in
Normal Epithelial Tissues and Carcinomas
The expression of C1QA, C1QB, and C1QC genes was
analyzed between different carcinoma and normal tissue
counterparts using the Oncomine database. The threshold
was determined as the following values: p-value < 0.05, fold
change >2, and gene ranking in the top 10%. Carcinomas
included in this analysis were: bladder carcinoma, breast
cancer, cervical squamous cell carcinoma, esophageal carcinoma,
head-neck squamous cell carcinoma, clear cell renal cell
carcinoma (CCRCC), papillary renal cell carcinoma (PRCC),
liver hepatocellular carcinoma, lung adenocarcinoma, lung
squamous cell carcinoma, ovarian cancer, pancreatic ductal
adenocarcinoma, rectum adenocarcinoma, gastric carcinoma,
and uterine corpus endometrial carcinoma. We only investigated
carcinomas in which all the three C1q chains showed a
significant prognostic effect by Kaplan-Meier plotter analysis.
The C1QA, C1QB, and C1QC genes were either over-
expressed, or downregulated depending on the type of carcinoma
investigated, as compared to their normal tissue counterparts.
All the three C1q chains showed a differential prognostic
significance. These data appear to suggest that C1q can have pro-
or anti-tumorigenic implications, depending on the carcinoma
types (Table 1). Thus, detailed analyses of the expression profiles
of all three C1q chains were performed.
Significance of C1q Expression in Breast
Carcinoma
Bioinformatics analysis of C1QA, C1QB, and C1QC mRNA
expression was performed in the context of the breast cancer
using Karnoub’s, Finak’s, Curtis’s, and Perou’s datasets. A higher
expression level of the three chains of C1q was detected as
compared to normal breast tissue (Figure 1A, p<0.05). When
breast cancer was stratified into different histological subtypes,
C1QA, C1QB, and C1QCmRNA expression achieved a statistical
significance only in medullary carcinoma (Figure 1B, p<0.05).
To evaluate the prognostic significance of C1q in all breast
cancers, we considered their molecular classification, such as
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TABLE 1 | Prognostic significance of C1q in patients with carcinomas.
CANCER Cancer subtype Gene symbol DFS/PFS OS
n = number of patients
Breasta Triple-negative C1QA HR = 0.47 (0.34–0.66) HR = 0.52 (0.32–0.85)
n = 618 for DFS p-value (4.7e-6) p-value (0.0079)
n = 241 for OS
Breasta Triple-negative C1QB HR = 0.56 (0.43–0.72) HR = 0.46 (0.28–0.75)
n = 618 for DFS p-value (5.6e-6) p-value (0.0014)
n = 241 for OS
Breasta Triple-negative C1QC HR = 0.58 (0.42–0.8) HR = 0.38 (0.2–0.71)
n = 360 for DFS p-value (0.0009) p-value (0.0019)
n = 153 for OS
Breasta Luminal A C1QA HR = 1.31 (1.1–1.55) ns
n = 1,933 for DFS p-value (0.0021)
n = 611 for OS
Breasta Luminal A C1QB HR = 1.54 (1.29–1.83) HR = 2.09 (1.47–2.97)
n = 1933 for DFS p-value (1.0e-6) p-value (2.6e-5)
n = 611 for OS
Breasta Luminal A C1QC HR = 1.36 (1.07–1.74) ns
n = 841 for DFS p-value (0.0132)
n = 271 for OS
Breasta Luminal B C1QA ns ns
n = 1,149 for DFS
n = 433 for OS
Breasta Luminal B C1QB ns ns
n = 1149 for DFS
n = 433 for OS
Breasta Luminal B C1QC ns ns
n = 407 for DFS
n = 129 for OS
Breasta HER2+ C1QA HR = 0.49 (0.33–0.72) HR = 0.17 (0.08–0.39)
n = 251 for DFS p-value (0.0002) p-value (2.1e-6)
n = 117 for OS
Breasta HER2+ C1QB HR = 0.61 (0.37–0.99) HR = 0.26 (0.12–0.55)
n = 251 for DFS p-value (0.0434) p-value (0.0001)
n = 117 for OS
Breasta HER2+ C1QC ns HR = 0.28 (0.13–0.63)
n = 156 for DFS p-value (0.001)
n = 73 for OS
Kidneyb Clear cell renal cell carcinoma C1QA HR = 1.76 (1.3–2.38)
n = 530 for OS p-value (0.0002)
Kidneyb Clear cell renal cell carcinoma C1QB HR = 1.55 (1.15–2.1)
n = 530 for OS p-value (0.0035)
Kidneyb Clear cell renal cell carcinoma C1QC H = 1.65 (1.21–2.24)
n = 530 for OS p-value (0.0012)
Kidneyb Papillary renal cell carcinoma C1QA ns
n = 287 for OS
Kidneyb Papillary renal cell carcinoma C1QB ns
n = 287 for OS
Kidneyb Papillary renal cell carcinoma C1QC ns
n = 287 for OS
(Continued)
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TABLE 1 | Continued
CANCER Cancer subtype Gene symbol DFS/PFS OS
n = number of patients
Lungc Adenocarcinoma C1QA HR = 2.11 (1.66–2.68)
n = 720 for OS p-value (6.4e-10)
Lungc Adenocarcinoma C1QB HR = 1.83 (1.45–2.31)
n = 720 for OS p-value (2.0e-7)
Lungc Adenocarcinoma C1QC HR = 3.29 (2.39–4.52)
n = 673 for OS p-value (9.9e-15)
Lungc Squamous cell carcinoma C1QA ns
n = 524 for OS
Lungc Squamous cell carcinoma C1QB ns
n = 524 for OS
Lungc Squamous cell carcinoma C1QC HR = 0.64 (0.46–0.89)
n = 271 for OS p-value (0.0084)
aUsing 5,143 cancer samples on the HGU133 Plus 2.0 array from Gene Expression Omnibus, GEO.
bUsing 817 cancer samples on the RNA HiSeq data from The Cancer Genome Atlas, TCGA.
cUsing 2,437 cancer samples on the HGU133 Plus 2.0 array from GEO.
DSF, disease-free survival; OS, overall survival.
luminal-A, luminal-B, HER-2 positive, and basal-like cancers
(BLBC) (Supplementary Table 2).
According to Kaplan-Meir plotter data, C1QA, C1QB, and
C1QCmRNA expression was positively associated with a disease-
free survival (DFS) rate in patients with BLBC (Figure 1C,
p<0.05) and with an overall survival (OS) rate with HER-2
positive cancers (Table 1). This correlation was not evident in
luminal-A and luminal-B patients. OnlyC1QBmRNA expression
was negatively associated with high DFS and OS rates in the
breast cancer patients with luminal-A, and to a DFS rate with all
breast cancer.
The IHC analysis within the BLBC microenvironment
revealed that C1q was diffusely present in the tumor stroma and
was expressed by macrophage-like cells, suggestive of tumor-
infiltrating myeloid elements (Figure 2A).
C1q Expression in Kidney Carcinoma has a
Negative Correlation
The C1QA, C1QB, and C1QC mRNA expression was evaluated
in kidney cancer based on the results obtained from different
datasets. In CCRCC, the expression of the three C1q chains
was higher as compared to normal kidney (Figure 3A, p<0.05).
However, in the case of PRCC, this trend was evident only
for C1QA and C1QB mRNA expression (data not shown). The
data obtained from Kaplan-Meier plotter showed a negative
relationship between C1QA, C1QB, and C1QCmRNA expression
and OS rate of patients with CCRCC (Figure 3B, p < 0.05).
No correlation was observed between C1QA, C1QB, and C1QC
mRNA expression and OS in the PRCC patients (Table 1).
Within the CCRCC microenvironment, C1q was found to
be mainly expressed in the tumor stroma and in the small
vessels, and it was associated with the cell membrane of tumor
cells (Figure 2B).
Lower Level of C1q Expression in Lung
Carcinoma
While examing C1QA and C1QB mRNA expression in lung
cancer, using Selamat’s, Wachi’s and Bhattacharjee’s datasets, we
found a lower expression level in adenocarcinoma (Figure 3C,
p<0.05) and in squamous cell carcinoma (data not shown,
p<0.05) than in normal lung tissue; C1QC mRNA expression
was significant only in lung adenocarcinoma. As shown in
Figure 3D, C1QA, C1QB, and C1QC mRNA expression levels
negatively correlated with an OS rate of the patients with lung
adenocarcinoma (p<0.05); no correlation with OS was observed
in squamous cell carcinoma (Table 1).
IHC in lung adenocarcinoma revealed C1q staining in the
stroma and some macrophage-like positive cells into the tumor
mass (Figure 2C).
DISCUSSION
In this paper, we performed bioinformatics analysis to explore if
C1q level could act as a possible prognostic marker in various
carcinomas, in view of its reported dichotomous effects on
cancer cells (pro- and anti-tumorigenic). C1q is present in colon,
lung, breast, pancreatic carcinoma, and melanoma. C1q can
promote adhesion, proliferation and migration of melanoma
cells (17). We found C1q in abundance in all histological
variants (epithelioid, sarcomatoid, and biphasic) of asbestos-
induced malignant pleural mesothelioma. C1q bound high and
low molecular weight HA and acted as a tumor-promoting
factor (18). In addition, C1q exerted a protective effect against
apoptosis, suggesting an overall pro-tumorigenic activity (17).
However, Hong et al. recently observed that C1q, expressed
in normal prostate, was downregulated in benign prostatic
hyperplasia and prostate cancer (15). C1q was able to induce
apoptosis and growth suppression of human prostate DU145
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FIGURE 1 | C1QA, C1QB, and C1QC expression in invasive breast carcinoma. Curtis’s datasets were used for bioinformatics analysis to explore C1QA and C1QB
mRNAs expression in the breast cancer, whereas Perou’s datasets was used for bioinformatics analysis to evaluate C1QC mRNA. A higher C1q mRNAs expression
was detectable in invasive breast carcinoma compared to normal breast tissue (A). The analysis of the different breast carcinoma histotypes by Finak’s dataset
revealed how the medullary breast cancer presented the major intensity of C1q mRNA expression (B). According to the data Kaplan-Meir plotter, C1QA, C1QB, and
C1QC mRNA expressions was positively linked to a disease-free survival (DFS) rate in patients with basal-like cancers (C) (p<0.05) and to an overall survival (OS) rate
with HER-2 positive cancers (Supplementary Table 2). HR, hazard ratio.
cells, through direct activation of the tumor suppressor WW-
domain containing oxidoreductase (WOX1). C1q also have a
pro-apoptotic effect on an ovarian cell line, SKOV3, acting via
a TNF-α induced apoptosis pathway that involves upregulation
of Bax and Fas (16).
In a syngeneic murine model of melanoma in C57BL/6 strain,
C1q-deficient mice showed prolonged survival and slower tumor
growth, as compared to wild-type mice (17). However, Bandini
et al. found that neuT mice, a genetically engineered mouse
model for mammary carcinoma that was made deficient for
the C1qA chain (neuT-C1KO mice), manifested an accelerated
tumor growth associated with an increased number of intra-
tumoral vessels, compared to wild-type neuT mice. These
differences in tumor progression were attributed to a reduced
activation of WW domain containing oxidoreductase (WWOX)
in C1q–deficient mice (25).
In view of these rather contradicting roles of C1q in tumor
progression, we performed a systematic bioinformatics analysis
of the expression of C1q, and its correlation with the survival rate
in different carcinoma histotypes, using Oncomine and Kaplan-
Meier plotter tools. We selected the carcinomas that showed
all the three chains of human C1q statistically significant for
the prognosis; in several cases, the prognosis was differentially
linked to the C1q chains, or limited to one or two C1q chains.
We often noticed the mRNA encoding for only one or two C1q
chains, something that would impede synthesis of a functional
C1q molecule. Indeed, we have provided evidence in the past
that the expression of C1qC chain is essential for the production
of functional C1q by the endothelial cells of the decidua (26).
Moreover, mesothelioma cells are impaired in C1q A chain
synthesis (18).
Our bioinformatics analysis highlighted that high levels of
C1q have a favorable prognostic index in BLBCs for DFS and
HER2+ breast cancer for OS, (Graphical Abstract) consistent
with the in vivo studies by Bandini et al. using C1q-deficient
mice (25). Inflammation is a major characteristic of these
types of tumors. One possible explanation for the observed
positive association between C1q expression and favorable
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FIGURE 2 | Immunohistochemistry analysis for C1q in breast (A), kidney (B) and lung carcinoma (C). Representative microphotographs showing expression of C1q in
different carcinoma. The expression of C1q in carcinoma was observed in all tissues with differential distribution in the TME, as described in the result section. DAB
(brown) chromogen was used to visualize the binding of anti-human C1q antibodies; scale bars, 50µm.
prognostic index could be due to the correlation between the
presence of C1q and dendritic cells (CD11c positive cells) in
TME. High CD11c expression in BLBCs is associated with a
significantly higher OS (p = 0.047) as compared to low CD11c
expression (27). Dendritic cells themselves can be a potential
source of C1q within the TME (28, 29). C1q, although present,
is not able to bind BLBC cells (MDA-MB-231), and hence,
not able to promote tumor progression (unpublished data),
probably due to downregulation of putative C1q receptor(s).
It is thus crucial to understand the differences in good
prognosis survival between BLBCs and HER2+ breast cancer,
the role of inflammation, and that of C1q in determining
such differences.
Wilson et al. (30) found that C1q chain genes were enriched
in the stroma compartment of triple-negative breast cancers.
The analysis of publicly available data sets revealed that the
genes encoding for the C1q chains were associated with a poor
prognosis in BLBC using the TCGA dataset (504 patients). In
our analysis, using the GEO dataset that include 5,143 patients,
we observed a positive prognostic effect for BLBCs in DFS and
HER2-positive breast cancers in OS. The opposite results were
obtained for CCRCCs and lung adenocarcinomas in OS.
A negative prognostic effect arose from the analysis of kidney
and lung carcinomas (Graphical Abstract). The most frequent
histological subtypes include CCRCC and PRCC (CCRCC
∼75%; PRCC ∼10%) (31). The expression of C1q in kidney
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FIGURE 3 | Pathological significance of C1q expression kidney and in lung cancer. Gumz’s dataset have explored C1QA and C1QB mRNA expression in kidney,
whereas Higgins’ dataset were used for C1QC mRNA expression. A higher C1q expression was detectable in CCRCC cancer than that in normal tissue (A), p < 0.05.
According to the data from Kaplan-Meier plotter, C1q mRNA expressions were negatively related to an overall survival rate of the patients with CCRCC (B). HR,
hazard ratio. Selamat’s dataset have revealed a lower C1QA and C1QC mRNA expression in lung adenocarcinoma that in normal lung tissues (C), whereas
Bhattacharjiee’s dataset was used for C1QB, but the results were in accordance with Selamat’s one. There was a negative association between C1q mRNA
expression and a favorable prognosis in patients with lung cancer, for Kaplan-Meir plotter (D). HR, hazard ratio.
cancer is increased as compared to normal kidney tissue
(Figure 3A) and C1q has a negative prognostic effect in the case
of CCRCC (Figure 3B); no association was evident for PRCC.
CCRCC tumor is characterized by an increased response to HIF
that promotes blood vessel growth. Targeted therapies directed
against VEGF, VEGF receptor, and mTOR play a crucial role in
the management of metastatic CCRCC (32). We can hypothesize
that C1q can also participate in promoting angiogenic processes
in this particular tumor (14).
C1q has a negative prognostic value in lung tumors limited
to adenocarcinomas, the most common form of lung cancer
(Figure 3D). According to the WHO classification of lung
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tumors, there are fourmajor histological types: adenocarcinomas,
squamous cell carcinomas, large cell carcinomas, and small cell
carcinomas (33). It is worth noting that C1q expression is reduced
in lung cancer compared to the normal lung as we observed
for surfactant protein D (SP-D) (34). Although C1q expression
in lung cancer is lower than in normal tissue, lung cancer cells
bind C1q present in the tumor microenvironment and activate
the classical complement pathway (35). Tumor transformation is
also concomitant with the loss of key defense molecules entrusted
with early recognition and removal of the altered self (36).
A number of factors can modulate the role of C1q in the
TME. C1q interaction with the ECM components can adversely
interrupt its putative functions, as is the case with HA. It is
also possible that certain tumors downregulate the putative
receptor for C1q in order to escape possible apoptosis induction.
Proliferative and apoptotic responses to C1q can be dictated by
distinct receptors that are yet to be discovered. Last but not the
least, the orientation of the C1q molecule, while engaging with
the tumor cells, can also define the C1q-mediated implications.
Our study encompasses all the above-mentioned possibilities,
including tumor heterogeneity.
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